TF Capital Management is a China-focused venture capital firm specializing in early-stage biopharmaceutical investments. Operating from Shanghai, the firm positions itself as a first-money investor in innovative biotech companies across China, providing full value-chain support from proprietary sourcing through exit. TF Capital manages approximately $1 billion in assets under management and has built a portfolio of over 100 biotech companies. The firm has achieved notable exits with more than 20 IPOs and 15 additional portfolio companies in IPO filing. TF Capital has also facilitated $2.8 billion in licensing deals across 25 transactions involving 14 portfolio companies over five consecutive years with multinational pharmaceutical corporations, demonstrating strong commercial validation and exit capabilities in the Chinese biopharma ecosystem.

Profile auto-generated from public sources — details unverified.